FDA greenlights AstraZeneca’s Imfinzi combo in bladder cancer breakthrough

The study tracked patients for more than five years (median 60.7 months), with protection against disease returning emerging in under four months and continuing long term

Pfizer's LORBRENA delivers landmark seven-year survival results in advanced lung cancer trial

The findings mark one of the longest progression-free survival outcomes ever reported in advanced lung cancer

Merck’s experimental cancer drug wins FDA breakthrough status in key lung cancer setting

The designation marks the first Breakthrough Therapy recognition for calderasib and is backed by positive results from the Phase 1 KANDLELIT-001 clinical trial

Glenmark posts strong FY26 results with 27.5% revenue jump

AstraZeneca reports mixed Phase III results for anselamimab in rare cardiac amyloidosis trial

The programme evaluated anselamimab as a first-line add-on to standard plasma cell dyscrasia therapy in patients with advanced cardiac AL amyloidosis

IIT Madras’s injectable hydrogel could reduce fibrosis treatment cost by 85%

Lupin's novel cancer therapy LNP8701 shows encouraging results in phase 1 trial

First-in-human study of investigational SOS1 inhibitor shows encouraging safety profile and early anti-tumor activity in patients with metastatic solid tumors

India’s MedTech industry is entering its defining decade: Dr. Shravan Subramanyam, MD, BPL Medical Technologies

From import dependence to global leadership, the next phase of growth must be driven not only by manufacturing scale and policy support, but also by innovation, research, and globally competitive healthcare technologies

AbbVie wins FDA nod for DECNUPAZ in rare blood cancer

BPDCN typically presents with skin lesions before rapidly spreading to the bone marrow, lymph nodes

Novo Nordisk to showcase late-stage pipeline & semaglutide expansion at ADA 2026

The company is set to unveil new clinical data across obesity, diabetes, kidney, and liver disease programs